88IV - PR Newswire Asia's news


Earendil Labs Announces First Patient Dosed in a Phase IIa Trial of a Half-life Extended Anti-TL1A Antibody (HXN-1001) in Patients with Ulcerative Colitis WILMINGTON, Del. , April 2, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced the first patient has been dosed in a Phase ... 2026-04-02T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
StairMed Secures RMB 500 Million Financing Led by Alibaba, Joined by Tencent SHANGHAI , April 2, 2026 /PRNewswire/ -- Shanghai StairMed Technology Co., Ltd. ("StairMed" or "the Company") recently announced the closing of a strategic financing round totaling ... 2026-04-02T Biotechnology Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association's 2026 Scientific Sessions Preclinical research on Caliway's fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the American Diabetes Association's 2026 ... 2026-04-02T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Telix Appoints David Gill as Non-Executive Director MELBOURNE, Australia and INDIANAPOLIS , April 2, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the appointment of David Gill as a Non-Executive ... 2026-04-02T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting - Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of atopic ... 2026-04-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Sino Biological ProPure™ Endotoxin-Free Proteins: The "Invisible Guardian" of Biopharmaceuticals HOUSTON , April 1, 2026 /PRNewswire/ -- After months of meticulous work, your cells suddenly behave unpredictably, or your mouse models develop fever and systemic inflammation during critical studies. ... 2026-04-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma SHANGHAI , April 1, 2026 /PRNewswire/ -- 31 March 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256) announced that its independently developed, ... 2026-04-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development PRINCETON, N.J. and TOKYO , April 1, 2026 /PRNewswire/ -- NJ Bio, Inc. ("NJ Bio"), a leading provider of integrated drug discovery and development services and Ajinomoto Bio‑Pharma Services ... 2026-04-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics' geographical diversification and establishes its first U.S. manufacturing presence, expanding ... 2026-03-31T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Co-PSMA data published in the European Urology journal SYDNEY , March 31, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation ... 2026-03-31T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

PR Newswire Asia's news > Biotechnology